lutetium lu-177 vipivotide tetraxetan - Profile

What are the generic sources for lutetium lu-177 vipivotide tetraxetan and what is the scope of freedom to operate?

Lutetium lu-177 vipivotide tetraxetan is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lutetium lu-177 vipivotide tetraxetan has one hundred and thirty-seven patent family members in thirty-nine countries.

Summary for lutetium lu-177 vipivotide tetraxetan

International Patents:	137
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for lutetium lu-177 vipivotide tetraxetan

Constraining patent/regulatory exclusivity:

10,398,791

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for lutetium lu-177 vipivotide tetraxetan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	12,208,102
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	11,951,190
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	11,318,121		Y	Y
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	10,406,240		Y	Y
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	10,398,791		Y	Y
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes

International Patents for lutetium lu-177 vipivotide tetraxetan

Country	Patent Number	Title	Estimated Expiration
Japan	2024117783
Japan	2018058847	前立腺特異的膜抗原（ＰＳＭＡ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用 (LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER)
Spain	3030116
Japan	2024059640
Hungary	E047200
Japan	2014221779
Australia	2019255692

Supplementary Protection Certificates for lutetium lu-177 vipivotide tetraxetan

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
4095130	2024C/528	Belgium		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; AUTHORISATION NUMBER AND DATE: EU/1/22/1703 20221212
4095130	C202430029	Spain		PRODUCT NAME: LUTECIO (177LU) VIPIVOTIDA TETRAXETANO; NATIONAL AUTHORISATION NUMBER: EU/1/22/1703; DATE OF AUTHORISATION: 20221209; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1703; DATE OF FIRST AUTHORISATION IN EEA: 20221209
4095130	2490022-7	Sweden		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130	CA 2024 00027	Denmark		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDETETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130	CR 2024 00027	Denmark		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDETETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130	C04095130/01	Switzerland		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTID TETRAXETAN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68684 24.02.2023
4095130	122024000038	Germany		PRODUCT NAME: (177LU)LUTETIUMVIPIVOTIDTETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703 20221209

Lutetium Lu-177 Vipivotide Tetraxetan (PLUVICTO): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Lutetium Lu-177 Vipivotide Tetraxetan (PLUVICTO) is a radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressions, approved by the FDA in March 2022 for metastatic castration-resistant prostate cancer (mCRPC). It leverages targeted radioligand therapy (RLT) to deliver radiotherapy directly to cancer cells, offering a novel treatment paradigm within oncology. This report assesses the investment landscape, prevailing market dynamics, and forecasted financial trajectory, integrating regulatory, competitive, and scientific factors influencing PLUVICTO’s commercial prospects.

---

Introduction

Aspect	Details
Generic Name	Lutetium Lu-177 vipivotide tetraxetan
Brand Name	PLUVICTO
Manufacturer	Advanced Accelerator Applications (AAA), Sanofi
Approval	FDA (March 2022), EMA (June 2022)
Indication	Metastatic castration-resistant prostate cancer (mCRPC)

Investment Scenario

Segment	Key Insights
Market Opportunity	Estimated global mCRPC market exceeding USD 7 billion in 2022; radioligand therapy expanding rapidly.
Investment Drivers	- FDA approval as a first-in-class therapy.
	- Increasing prevalence of advanced prostate cancer (~55,000 new cases annually in the US).
	- Strategic collaborations with key pharma and biotech entities.
Commercialization Concerns	- High manufacturing complexity for radiolabeled agents.
	- Limited number of competitors currently, but pipeline competition anticipated.
Regulatory Pathways	- Breakthrough Therapy Designation (BTD) enhances review timelines.
	- Potential for accelerated approval in other jurisdictions (EMA, PMDA, etc.).

Market Dynamics

Global Prostate Cancer Landscape

Metric	Data
Incidence (2022)	~1.4 million new cases globally annually (source: WHO).
Proportion mCRPC	Approximately 10-20% of prostate cancer patients develop castration-resistant disease.
Key Markets	US, EU, Japan, China – driven by aging populations and prostate cancer burden.

Competitive Environment

Competitors	Key Drugs/Agents	Status	Notes
Pluvicto (Lutetium Lu-177 vipivotide tetraxetan)	FDA-approved, first-in-class PSMA-targeted RLT	Marketed	Clinical data shows OS benefit (~15 months median OS).
$19B Market	-	-	Rival options include chemotherapy, AR-targeted therapies, immunotherapies.
Potential Pipeline Candidates	-	Bismutine, Actinium-225-Lutetium conjugates	Early-stage or preclinical, could affect long-term market share.

Regulatory and Reimbursement Dynamics

Elements	Impact
Reimbursement Policies	CMS and private insurers covering radioligand therapies approved via FDA pathways.
Reimbursement Challenges	High costs (~$100K–$150K per treatment cycle) require robust health economic evaluations.
Clinical Adoption	Early adoption driven by demonstrating improved survival and quality of life.

Financial Trajectory Forecast

Revenue Projections

Year	Approximate Global Sales (USD Millions)	Key Assumptions
2022	USD 200–300	Initial launch in US, limited market penetration.
2023	USD 500–700	Expanded access, international launches, uptake in clinical practice.
2024	USD 1.2–1.8 billion	Broader adoption, reimbursement stabilization, pipeline additions.
2025+	USD 2+ billion	Growth fueled by second-line applications, combination therapies.

Revenue Drivers

• Market Penetration: Rapid uptake in approved regions.
• Pricing Strategies: Premium pricing justified by clinical benefits.
• Reimbursement Coverage: Securing favorable payer policies.
• Pipeline Expansion: Additional indications (e.g., other PSMA-positive cancers), combination regimes.

Cost Structures

Cost Element	Approximate Impact
Manufacturing & Supply Chain	High due to radiolabel synthesis complexity.
Clinical Development & R&D	Ongoing, particularly pipeline expansion.
Regulatory & Distribution	Significant, especially for international markets.
Market Access & Education	Critical for physician adoption; marketing costs high.

Comparison with Competitive Radiopharmaceuticals

Agent	Target	Approval Status	Key Data	Market Potential
Pluvicto	PSMA receptor targeting for prostate cancer	FDA, EMA approved	Median OS extension (~15 months), ORR 40%	Leading position, first-mover advantage
Radium-223 (Xofigo)	Bone metastases in prostate cancer	Approved, long history	OS benefit (~3 months), well-established	Market saturation, but limited to bone metastases
Actinium-225 compounds	Emerging, targeted alpha therapy	Preclinical/early clinical	Potential for higher efficacy	Future competition, high development risk

---

Regulatory and Scientific Considerations

Aspect	Impact
Approval Milestones	Accelerated approval by FDA demonstrates high unmet need fulfillment.
Label Expansion Strategy	Clinical trials targeting earlier lines of therapy and other tumor types.
Manufacturing Scale-up	Strategic investments to ensure consistent supply of radionuclide compounds.
Safety Profile	Favorable, with manageable hematologic and dry-mouth adverse events.

---

Key Market Challenges and Opportunities

Challenges	Opportunities
High treatment costs leading to reimbursement negotiations	Growing demand for personalized, targeted therapies.
Limited healthcare infrastructure for RLT in some regions	Expanding global access through partnerships and infrastructure investments.
Competition from pipeline agents or emerging modalities	Continued innovation, combination strategies, and early-line approvals.
Regulatory hurdles across jurisdictions	Fast-track designations and collaborative regulatory pathways.

---

FAQs

1. What factors contributed to FDA approval of Lutetium Lu-177 Vipivotide Tetraxetan?
The FDA approved PLUVICTO based on Phase 3 VISION trial data demonstrating significant overall survival benefits (~15 months median OS) and manageable safety profile in mCRPC patients with PSMA-positive metastases. Breakthrough Therapy Designation expedited review.

2. How does PLUVICTO compare with existing therapies for prostate cancer?
PLUVICTO offers targeted radioligand therapy directly delivering radiation to PSMA-expressing tumors, showing improved OS relative to prior treatments such as chemotherapy and AR-targeted therapies, especially in late-stage disease.

3. What are the primary barriers to commercial success?
Manufacturing complexity of radiopharmaceuticals, high treatment costs, limited infrastructure, and reimbursement hurdles pose significant barriers. Physician awareness and patient access are critical for uptake.

4. What is the potential for combination therapies involving PLUVICTO?
Combining PLUVICTO with androgen receptor pathway inhibitors or immunotherapies is under evaluation, aiming to enhance efficacy and delay resistance, representing a key growth avenue.

5. How might international markets influence PLUVICTO’s financial trajectory?
Regulatory approvals outside the US, such as EMA and Japanese approvals, will expand market access. Variations in healthcare infrastructure and reimbursement policies will influence revenue growth.

---

Key Takeaways

• Market Leadership Potential: As the first FDA-approved PSMA-targeted radioligand therapy, PLUVICTO holds a significant early-mover advantage in a high unmet need tumor type.
• Rapid Growth Trajectory: Projected revenues could reach over USD 2 billion globally by 2025, contingent on sustained adoption, reimbursement, and healthcare infrastructure expansion.
• Competitive Landscape: Limited immediate competitors bolster market share, but pipeline threats and emerging modalities warrant strategic vigilance.
• Regulatory and Manufacturing Foundations: Continued engagement with regulators and investment in manufacturing capabilities are vital for long-term success.
• Investment Risks and Rewards: High development and manufacturing costs are balanced by substantial clinical benefits and market demand, suggesting favorable risk-adjusted returns if commercialization strategies are effectively executed.

---

References

[1] U.S. Food and Drug Administration. (2022). FDA Approves Pluvicto for Metastatic Prostate Cancer.
[2] WHO. (2022). Global Cancer Statistics.
[3] Sanford, et al. (2022). Clinical outcomes with Lutetium Lu-177 vipivotide tetraxetan in mCRPC. The New England Journal of Medicine.
[4] EvaluatePharma. (2022). The World Market for Radiopharmaceuticals.
[5] European Medicines Agency. (2022). Summary of Product Characteristics for Lutetium Lu-177 vipivotide tetraxetan.

---

This detailed review provides a comprehensive understanding of PLUVICTO’s investment outlook, market drivers, and financial future, essential for strategic decision-making in the pharmaceutical investment sector.